Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims align with the label (class/indication framework, SC administration, ART/OI use, OHSS risk, injection site disorders, and contraindications concept). However, multiple specific or mechanistic/dosing timing claims are not supported by the provided label excerpts (e.g., PCOS/half-life details, exact dosing schedule length/daily frequency, starting on trigger day, urine vs recombinant derivation, clomiphene/GnRH adjuncts, specific adverse effects like headache/nausea, allergic reactions).
Category Scores
Accurate Statements
Ovidrel belongs to the class of medications called gonadotropins.
Label describes Ovidrel/choriogonadotropin alfa as a potent gonadotropic substance (Section 5).
Ovidrel is typically administered by subcutaneous injection (under the skin).
Label: 'For Subcutaneous Use Only' and 'intended for a single subcutaneous injection' (Sections 2, Directions for Administration).
Ovidrel is used in assisted reproductive technology (ART) to stimulate ovulation in women with PCOS or other ovulation disorders.
Label indicates ART use for induction of final follicular maturation and early luteinization in infertile women as part of ART programs such as IVF/embryo transfer (Section 1). Label also indicates Ovidrel for induction of ovulation (OI) in anovulatory infertile patients with functional cause not due to primary ovarian failure (Section 1).
Ovidrel can cause more serious side effects such as ovarian hyperstimulation syndrome (OHSS).
Label warnings: 'capable of causing Ovarian Hyperstimulation Syndrome (OHSS)' and detailed OHSS section (Section 5).
Ovidrel can cause side effects including injection site reactions.
Label adverse reactions include 'Application site disorders' and 'Injection site pain' examples (Section 6).
Unsupported Statements
Ovidrel (choriogonadotropin alfa) is used to stimulate ovulation in women with polycystic ovary syndrome (PCOS) or other ovulation disorders.
Provided label excerpt describes OI in anovulatory infertile patients with a functional cause not due to primary ovarian failure, but does not mention PCOS specifically (Section 1).
Ovidrel gonadotropins are derived from human urine or recombinant DNA technology.
No derivation source (urine vs recombinant DNA) is stated in the provided label excerpts (Sections 1-14 provided).
Ovidrel is typically injected subcutaneously once a day for 5-6 days.
The provided label dosing for ART/OI indicates administration 'one day following the last dose of the follicle stimulating agent' and does not specify a once-daily 5-6 day regimen (Section 2).
Ovidrel is started on the day of ovulation triggering.
The label excerpt specifies administration timing relative to the last dose of the follicle stimulating agent, and also requires adequate follicular development by estradiol and transvaginal ultrasound; it does not state 'started on the day of ovulation triggering' (Section 2).
Ovidrel works by stimulating the release of an egg from the ovaries.
The label excerpt provides receptor binding and induction of ovulation/OI, but does not provide the exact mechanism phrasing 'stimulating the release of an egg' (Sections 1, 12).
Ovidrel increases the likelihood of ovulation.
While ovulation induction is an indicated use, this specific probabilistic phrasing is not explicitly stated in the provided label excerpt (Section 1).
Ovidrel has a relatively short half-life.
No half-life information is provided in the supplied label excerpts (Section 12 excerpt provided does not include half-life).
Ovidrel’s short half-life allows it to be administered in a short treatment cycle.
Half-life and rationale for cycle length are not supported by the provided excerpts (Section 12 and Section 2 do not provide this justification).
Ovidrel is often used in conjunction with other fertility medications such as clomiphene citrate.
No mention of clomiphene citrate is present in the provided label excerpts (Sections provided include no such drug-combination information).
Ovidrel is often used in conjunction with other fertility medications such as gonadotropin-releasing hormone (GnRH) agonists.
No mention of GnRH agonists is present in the provided label excerpts.
Ovidrel can help improve the chances of conception by increasing the number of eggs released by the ovaries.
The provided label excerpt does not make this specific 'chances of conception' or 'increasing number of eggs released' claim; it references oocyte retrieval similarity/comparisons in clinical studies without stating this causal statement (Sections 1, 14).
Ovidrel can cause side effects including headache.
The provided adverse reaction examples in the excerpt do not list headache (Section 6 excerpt provided only includes examples).
Ovidrel can cause side effects including nausea.
The provided adverse reaction examples in the excerpt do not list nausea (Section 6 excerpt provided only includes examples).
Ovidrel can cause more serious side effects such as allergic reactions.
No allergic reaction adverse reaction is included in the provided excerpt (Section 5 contraindications mention hypersensitivity, but not an adverse reaction category for 'allergic reactions' as a side effect).
The patent for Ovidrel expires in an unspecified year, which may affect availability and pricing of the medication.
No patent/availability/pricing statements are present in the provided label excerpts.
Contradictions
Moderate
AI Statement
Ovidrel is typically injected subcutaneously once a day for 5-6 days.
Label Reference
Label indicates Ovidrel 250 µg should be administered one day following the last dose of the follicle stimulating agent and is intended for a single subcutaneous injection; it does not describe a daily 5-6 day course (Section 2, Directions for Administration).
Important Omissions
Contraindications list (e.g., pregnancy, primary ovarian failure, hypersensitivity, uterine bleeding of undetermined origin, ovarian cyst/enlargement of undetermined origin, sex hormone dependent tumors, and uncontrolled thyroid/adrenal dysfunction/intracranial lesion).
Importance:
Moderate
Monitoring requirements: adequate follicular development using serum estradiol and vaginal ultrasonography; withholding administration with excessive ovarian response; follow patients for at least two weeks after hCG administration for OHSS risk; hospitalization if severe OHSS.
Importance:
Moderate
Drug interaction relevant to pregnancy tests: 'may interfere with the interpretation of pregnancy tests.'
Importance:
Moderate
Use in specific populations: renal/hepatic insufficiency not established; pediatric/geriatric safety/effectiveness not established.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Several statements are unsupported or inconsistent with the provided dosing/timing information (e.g., once daily for 5-6 days), and the response omits key label contraindications and monitoring instructions that are important for safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple unsupported specifics (PCOS mention, derivation source, exact dosing frequency/duration, trigger-day timing, half-life-based rationale, adjunct medications, and certain adverse effects) and omission of contraindications/monitoring and the pregnancy test interference note.
Suggested Improvement
Constrain claims to the supplied label excerpts: indicate the labeled indications (ART IVF/embryo transfer; OI in anovulatory infertile patients with functional cause not primary ovarian failure), follow labeled administration timing ('one day following the last dose' and single SC injection; withhold until adequate follicular development and with excessive response), include key contraindications (especially pregnancy) and monitoring (estradiol + transvaginal ultrasound; follow at least two weeks post-administration for OHSS), and avoid adding unsupported adverse reactions or formulation/source/patent information.